AI Threat Assessment · 27 May 2026

Indegene

Life Sciences Consulting
COOKED
6.8/ 10

“Indegene built a $400M life sciences consulting empire by understanding that pharma companies desperately need help navigating digital transformation but are too risk-averse to figure it out themselves. Twenty-five years of regulatory expertise, FDA submission workflows, and commercial analytics that kept Pfizer and Novartis coming back for more. The tragic irony is that they've spent two decades teaching AI exactly what good clinical data analysis looks like — and now Claude can run a Phase III statistical analysis faster than their Bangalore team can schedule the kickoff call.”

Business Model
7.5
Automation Risk
8.0
Moat Strength
4.5
Adaptability
6.0
Need Survival
5.5
AI Threat Level
BUSINESS MODEL REPLACEABILITY

Their sweet spot was 'we do the data science and regulatory consulting that pharma can't do in-house' — until GPT-4 started reading clinical trial protocols, and Claude began drafting FDA submissions that pass review on the first try. The billable hours model works beautifully right up until the hour count goes to zero.

7.5
WORKFORCE AUTOMATION RISK

Clinical data analysts, biostatisticians, and regulatory writers are discovering that AI can process adverse event reports, generate safety narratives, and draft clinical study reports with the thoroughness of a caffeinated PhD and none of the visa paperwork. The humans left standing will be the ones who know which questions to ask the AI — not the ones who know how to calculate p-values by hand.

8.0
MOAT STRENGTH

FDA relationship depth and 25 years of regulatory submission data create genuine switching costs — pharma clients don't casually change the team that knows their approval history. But the moat only holds if the deliverable still requires human judgment; once AI can draft the submission faster and more accurately, the relationship becomes expensive nostalgia.

4.5
AI ADAPTABILITY SIGNALS

They launched 'IndegenAI' in 2024 with all the enthusiasm of a consulting firm that just discovered machine learning exists, but their job postings still seek 'traditional biostatisticians' while their clients are already piloting Claude for protocol design. Classic innovator's dilemma: the AI tool that saves the client money costs Indegene the contract.

6.0
WILL THE NEED SURVIVE AI?

Pharma companies will always need regulatory submissions and clinical trial design — they just won't need 40 consultants and six months to do what AI accomplishes in a week. The need survives; the headcount delivery model doesn't.

5.5
Verdict

“AI doesn't kill the regulatory consulting — it just makes it clear that charging $300/hour for statistical analysis is really charging $300/hour for knowing how to use SAS, and SAS is no longer the hard part. Indegene's FDA expertise buys them a longer runway than pure-tech consultancies, but every AI-generated submission that passes review is another billing model funeral.”

Scores are based on public information and AI analysis. This is an affectionate roast, not a financial assessment. The best companies use this as a mirror, not a verdict.

Roast another →